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Concise summaries
• Spray (noncontact) cryotherapy delivered to
the esophagus via standard upper endoscope
induces necrosis extending into the submu-
cosa and inflammation into the muscularis
propria at doses currently being used clini-
cally. For Barrett’s high-grade dysplasia, the
lifetime risk of developing adenocarcinoma is
high, and cryoablation therapy is one of several
modalities that may prevent the development of
cancer.
• The clinical experience to date seems to suggest
that 10–15 sec freeze times may be adequate
for short-term efficacy in ablation of Barrett’s
esophagus (BE), but the optimum number of
freeze-thaw cycles for tissue ablation is still un-
clear. However, recent work presented at the
2010 OESO World Congress suggests an ability
to accomplish this with less than three treat-
ments, on average, and this may reflect advan-
tages gained by the shift toward a dosimetry of
2 × 20 sec, yielding a more robust treatment
response than 4 × 10 sec sprays.
• There are very limited data available to com-
pare the two cryotherapy methods, but high ef-
ficacy in elimination of early neoplasia in BE and
excellent safety profiles appear similar at this
time.
• Cryotherapy is probably no better than other
ablation modalities for palliation of bulky
esophageal cancers, but experience is limited. It
appears to cause tumor regression for extended
periods even if eradication is not possible.
• When sizing and ablation catheter selection
are performed according to instructions, cir-
cumferential ablation using radiofrequency ab-
lation (RFA) technology is a safe, effective
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procedure with a <0.02% perforation rate and
no patient deaths. The possibility of even larger
devices, and “one-size fits all” balloon devices
that unfurl or unroll to accommodate individ-
ual esophageal sizes and shapes, are also in the
development pipeline, and these would obviate
the need for balloon staging.
• With both RFA and cryotherapy, the strictures
that have been reported have for the most part
been responsive to single balloon dilation. Over-
all, the safety profile with RFA and cryotherapy
is significantly improved over PDT with RFA
currently with the most data in support of its
safety profile.
• Endoscopic ablation appears to achieve excel-
lent rates of ablation of Barrett epithelium and
Barrett-associated neoplasia; however, longer
follow-up is needed to identify risk factors for
persistence and recurrence, using regular and
careful biopsy surveillance strategies.
• Much remains unknown regarding the util-
ity of ablative therapy in Barrett’s. Although
preliminary data suggest that in both dysplas-
tic and nondysplastic Barrett’s, the neosqua-
mous epithelium is durable in mid-term re-
sults, further work will define the long-term
durability of the neosquamous reversion. The
cancer risk in treated subjects requires further
definition.
• There is some variability in recommendations
for dealing with low-grade dysplasia (LGD).
These recommendations vary from continu-
ing endoscopic biopsy surveillance every six
months for LGD for an indefinite period of
time, to antireflux therapy followed by endo-
scopic surveillance every one to three years.
• Concerning the progression of BE to HGD and
adenocarcinoma, the role of acid in increas-
ing or decreasing proliferation is still contro-
versial and uncertain. The results of the 10-year
prospective controlled trial Aspirin Esomepra-
zole Chemoprevention Trial (AspECT), to be
reported in 2014, will be of great importance to
making decisions concerning the use of proton
pump inhibitors (PPIs) on a continuous basis to
specifically decrease the risk of high-grade dys-
plasia (HGD) and adenocarcinoma in Barrett’s
patients.




This discussion focuses on spray (noncontact)
cryotherapy delivered to the esophagus via standard
upper endoscope. Two cryotherapy devices are cur-
rently available in the United States—a low-pressure
liquid nitrogen device (CryoSpray Ablation System,
CSA Medical, Inc., Baltimore, MD, USA) and a high-
pressure system using CO2 (Polar Wand, GI Supply,
Camp Hill, PA, USA). This device generates cold by
the Joule–Thomson effect, whereby rapid expansion
of gas at the catheter tip produces a significant de-
crease in temperature. In both techniques, tissue is
repeatedly frozen then allowed to thaw. These freeze-
thaw cycles induce tissue necrosis by direct freezing
(protein denaturation, extracellular, and intracellu-
lar ice formation, and cell membrane disruption),
tissue necrosis (vascular stasis, platelet aggregation,
and thrombosis), and cryotherapy-induced apop-
tosis. The procedures are performed using standard
endoscopic sedation and techniques in the outpa-
tient setting. To vent gas during the procedure,
a modified orogastric tube (cryo-decompression
tube) is placed prior to spraying and removed af-
ter treatment for the liquid nitrogen system, and
a suction catheter is attached to the tip of the en-
doscope in the CO2 system. Endoscopic treatment
sessions are repeated every four to six weeks as
needed.
Animal models were developed to test whether
these devices could successfully freeze esophageal
tissue and to develop appropriate dosimetry. Ini-
tial studies using a prototype of the liquid nitrogen
device involved 20 swine, with freeze time varying
between 10 and 60 sec.1 Follow-up endoscopy with
biopsy was performed on days 2, 7, 14, 21, and 28 to
assess cryotherapy effects and healing. Animals were
sacrificed after complete healing was documented,
and full-thickness samples of the treated area were
evaluated. Cryotherapy produced mucosal freezing
in all animals within 30 sec, and tissue thawed within
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one min after cessation of the spray. Follow-up en-
doscopy demonstrated varying degrees of injury
from superficial erosions to severe mucosal blister-
ing. Histologically, biopsies showed mild superficial
inflammation extending to the lamina propria in
mild cases but severe acute esophagitis extending
to the submucosa with separation of the squamous
epithelium in severe cases. Three swine developed
esophageal strictures, and histology showed trans-
mural acute inflammation from treatment in these
cases.
In initial studies of a prototype CO2 system,
mucosa was frozen in two dogs by spraying until
a white frost was seen.2 Superficial necrosis and
acute inflammation was seen on day 1 without
submucosal involvement. Re-epithelialization be-
gan by day 4 with complete healing by week 3. A
later study using the commercial CO2 device eval-
uated eight swine treated with varying duration of
spray (15, 30, 45, 60, 120 sec) followed by necropsy
two days later.3 Depth of necrosis and injury cor-
related with spray duration, with necrosis of the
mucosa/submucosa at 15–30 sec, muscularis pro-
pria at 45–60 sec, and adventitia (transmural) at
120 sec.
A human depth of injury study is ongoing at the
University of Miami, Miami, Florida.4 The liquid ni-
trogen device is being tested on normal esophageal
tissue seven days prior to planned cancer-related
esophagectomy, with assessment of inflammation,
hemorrhage, and necrosis. Dosimetries used are
10 sec freeze followed by thaw for four cycles and
20 sec freeze then thaw for two cycles. Preliminary
results in three patients indicate that inflammation
extends to the submucosa/muscularis propria and
necrosis to the mucosa/submucosa in the 10 sec
group, with inflammation to the muscularis pro-
pria and necrosis to the submucosa in the patient
treated for 20 sec.
In summary, the following has been learned
through the study of cryotherapy in animal and hu-
man models:
• spray cryotherapy can induce necrosis extend-
ing through the esophageal wall;
• depth of injury is determined by duration of the
cryotherapy spray and number of freeze-thaw
cycles; and
• in humans, spray cryotherapy induces necrosis
extending into the submucosa and inflamma-
tion into the muscularis propria at doses cur-
rently being used clinically.
2. What is the difference between liquid
nitrogen and carbon dioxide cryotherapy
systems with respect to efficacy and to
side effects?
Charles J. Lightdale, MD
cjl18@columbia.edu
Liquid nitrogen cryotherapy
This method uses a low-pressure spray of liquid ni-
trogen to freeze tissue at a very cold −196 ◦ C.5 The
special plastic catheter carrying the liquid nitrogen
gets very cold, as does the endoscope itself, and the
catheter routinely becomes unmovable in the biopsy
channel. There is a warm air pump to unfreeze the
system more rapidly. As the liquid nitrogen spray
freezes tissue, it warms to nitrogen gas, which ex-
pands and must be evacuated from the upper GI
tract. For this purpose, a special oral-gastric suction
tube with both active and passive suction is utilized.
This tube can sometimes be a technical obstacle. Ab-
dominal massage is also required during treatment
to help evacuate gas through the tube and through
the mouth. A clear plastic cap on the tip of the endo-
scope can help decrease the lens fogging associated
with the freezing spray.
Carbon dioxide cryotherapy
This method uses compressed carbon dioxide gas
spray through a catheter with a tiny opening at the
tip (0.005 inch diameter). The rapid expansion of
the room temperature carbon dioxide gas causes
cooling (Joule–Thomson effect) to −78 ◦ C, freezing
the targeted tissue.6 For gas evacuation, a cap-like
suction device is fixed to the endoscope tip with a
connecting flat suction tube along the side of the
endoscope. The suction cap can make endoscope
passage into the esophagus more difficult in some.
The endoscope and catheter do not freeze, and ab-
dominal massage is not required. The compressed
carbon dioxide gas reservoir is more stable than liq-
uid nitrogen, and the carbon dioxide system is less
expensive. Lens fogging during the treatment is also
a problem with this system.
Comparison of efficacy and side effects
Liquid nitrogen. In a series of 17 patients with
HGD in BE, the complete response (CR) for HGD
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was 94%, for all dysplasia (D) 88%, and for intestinal
metaplasia (IM) 53%.5 In a larger series of 60 pa-
tients with HGD, CR for HGD was 97%, D was 87%,
and IM was 57%.7 In 49 patients who completed
cryotherapy for stage T1 esophageal cancer, the CR
was 75%.8 Reported side effects in these series in-
clude variable chest pain and dysphagia, stricture
rate 3–13%, mostly related to prior therapies, and
one gastric perforation in a patient with Marfan’s
syndrome.
Carbon dioxide. In 44 patients, the CR for HGD
was 86%, D was 84%, and IM was 50%.9 Side ef-
fects were minimal chest discomfort, and no serious
adverse events.
Conclusions
There are very limited data available to compare
the two cryotherapy methods, but high efficacy in
elimination of early neoplasia in BE and excellent
safety profiles appear similar at this time. Further
studies are also needed to compare cryotherapy to
other ablative methods.




Cryotherapy is a means of tissue destruction that
can be used for the successful ablation of BE with or
without dysplasia. Short-term data suggest that this
treatment modality is both effective and safe. How-
ever, there are limited dosimetry data for cryother-
apy in BE. Cryotherapy results in two processes, the
freeze and the thaw, that both result in tissue dam-
age and destruction. During the freeze, there is direct
tissue injury via intra- and extra cellular ice crystal
formation. This in turn can lead to both rapid cell
death as well as delayed apoptosis several days after
treatment. Both faster rates of cooling and longer
duration of freeze increase the amount of ice crystal
formation. During the thaw period, there is recrys-
tallization and growth of ice crystals, which lead
to shear injury. Additionally, thrombosis of small
blood vessels occurs, leading to tissue hypoxia and
cell death. It is unclear whether the freeze or thaw
period is more important, or whether the number
of freeze-thaw cycles is the most important factor in
determining treatment effect.
Only a few dosimetry studies have been per-
formed with cryotherapy in the esophagus.3,10,11
Johnston et al. used liquid nitrogen spray to treat
the esophagus of 20 pigs, with freeze times ranging
from 10 to 60 sec.10 Observed tissue injury ranged
from superficial inflammation to coagulative necro-
sis on the submucosa. The degree of injury did not
appear to correlate with freeze time. In a pig model
study using cooled carbon dioxide, tissue damage
was limited to the submucosa for freeze durations
of 15 and 30 sec, but affected deeper layers with
longer durations.3 The clinical relevance of tissue
injury and necrosis to deeper layers of the esophagus
is unclear, as cryotherapy can result in preservation
of the extracellular matrix despite surrounding cell
death.
Clinical experience with various doses of
cryotherapy has demonstrated seemingly consistent
efficacy with a good safety profile. The initial dos-
ing regimen for liquid nitrogen spray in studies of
BE with HGD or adenocarcinoma was 20 sec times
three cycles. After a case of a patient with Marfan’s
syndrome who developed a gastric perforation due
to overdistention, the dosing protocol was changed
to 10 sec times four cycles. Both of these studies
demonstrated that liquid nitrogen cryotherapy was
efficacious and safe,7,8 although analyses comparing
efficacy in the patients who received (20 sec × 3)
versus (10 sec × 4) were not performed. There is
an ongoing study of CO2 cryotherapy, although
dosimetry, efficacy, and safety data are not yet
available.
In summary, cryotherapy produces a variable
depth of tissue injury based on duration of freeze,
the number of freeze-thaw cycles, and the distance
from the spray origin. The clinical experience to date
seems to suggest that 10–15 sec freeze times may be
adequate for short-term efficacy in ablation of BE.
The optimum number of freeze-thaw cycles for tis-
sue ablation is still unclear. Palliative treatment of
esophageal tumors is less clear. Longer freeze times
may be more effective in this population; this may
be accompanied by a theoretical increased risk of
perforation, although this has not been observed
clinically. Studies that compare various freeze dura-
tions and numbers of freeze-thaw cycles with clinical
outcomes are lacking.
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4. What are the criteria that determine the
mean number of cryotherapy sessions and
total length of treatment—is PPI therapy
concomitant to cryotherapy mandatory?
John D. Horwhat
john.david.horwhat@us.army.mil
As with any endoscopic technique, ideal application
will be influenced by factors that relate to the pa-
tient, the procedure and the physician. Presently,
cryotherapy remains a largely fledgling technology
that is only slowly finding a niche with endoscopists
that ablate BE. All (nonabstract) published data re-
lating to cryotherapy and BE have been with the
CSATM Medical device, and there is no published
consensus on dosimetry.7,8,12
With respect to patient-related factors, the ma-
jor determinants are the length of the segment
being treated and the goal of therapy. The aim of
each treatment cycle is to keep an area of mucosa
“painted” with a uniform white cryofrost for 20 sec
in the treatment of dysplasia and 30 sec for cancer.
Two cycles are typically given for a total treatment
dose of 40 sec (dysplasia) and 60 sec (cancer) respec-
tively. If one attempts to treat too large of a segment,
there is the risk that the distal mucosa could begin
to thaw as the scope is moved proximally, thus di-
minishing the uniformity of effect. In order to both
maintain direct visualization and to ensure that the
spray is applied for uniform freezing effect, a 3–4 cm
length is the largest segment that should be targeted
with each cycle. Whether one chooses to treat in a
hemicircumferential or fully circumferential man-
ner depends on the operators experience and ability
to maneuver around the decompression tube.
Another patient factor is the goal of therapy. If
the goal is regression from HGD to nondysplastic
BE, one may not need as many sessions as when the
goal is complete re-epithelialization to squamous
mucosa. Just as small islands of columnar appear-
ing tissue can remain after the application of RFA or
PDT that require addition HALO90TM or spot treat-
ment with APC, the same can occur with CSATM
and result in the need for an additional treatment
session.
Procedural factors relate to dosimetry, the abil-
ity to maintain visualization and to ventilate the
volume of gas that is instilled. During the earliest
work with CSATM, dosimetry required either four
10-sec freeze-thaw cycles or two 20-sec cycles per
segment treated. As experience developed and re-
finements in the dual-lumen decompression tube
(CDTTM) were made, most now use the 2 × 20 sec
dosimetry as this is quicker, easier to perform and
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appears to give a more robust response than the 10-
sec freeze-thaw cycles. Visualization and venting are
interrelated in that one may encounter some fogging
of the lumen after 12–15 sec of freezing. This can be
ameliorated by temporarily stopping the flow of gas
and allowing decompression to catch up. Recall that
liquid nitrogen expands nearly 700 times in volume
when changing from a liquid to gas with rewarm-
ing, and it is imperative that the decompression tube
ventilates this volume to reduce the risk of baro-
trauma. Since the inception of the CDTTM, overdis-
tention, and resultant barotrauma have been all but
eliminated.
Recent work performed by Ribiero et al. has con-
tributed greatly to our knowledge of dosimetry.13
Patients scheduled for esophagectomy had a 2 ×
2 cm2 area of mucosa targeted for cryospray with
either 4 × 10 sec or 2 × 20 sec. Seven days later at
esophagectomy the treated area was analyzed histo-
logically. The areas treated with 2 × 20 sec sprays
consistently achieved a depth of necrosis to the level
of the superficial or deep submucosa. This evidence
adds support to the basis for a dosimetry of 2 ×
20 sec in patients with dysplasia and further work
in this area is ongoing by these investigators.
Table 1 shows data from several centers as it re-
lates to dosimetry and includes nondysplastic Bar-
rett’s, dysplasia, and cancer. Abstract data presented
at OESO 2010 are included. The data from Dumot
et al. from the Cleveland Clinic are not shown as the
prototype devices and dosimetry changed multiple
times over the course of his study as the technol-
ogy evolved, and the data are too heterogeneous to
display. Even allowing for the evolution from hemi-
circumferential spraying to circumferential spraying
then from 4×10 sec sprays to 2×20 sec sprays, there
is a striking consistency among the various centers
for a number of treatment sessions that ranges from
3 to 4. Regarding the issue of whether acid control
is necessary during the application of cryotherapy,
the only data relating to CSATM ablation come from
the original pilot study with CSATM from Johnston
et al.12 All patients that entered into the trial that
had reversal of their Barrett’s to normal squamous
had complete acid control demonstrated by 24 h-pH
analysis upon entry to the study. Doses of medica-
tion were escalated for patients without acid control
and repeat testing done at higher dose to ensure an
anacid intraesophageal lumen was present during
the treatment and healing phases of the study. Sim-
ilarly, work with RFA from the Stanford group has
shown a statistically significant (P < 0.05) relation-
ship between acid control and treatment response,
emphasizing the need for acid control in patients
undergoing ablation.14
Summary
The current literature demonstrates the ability to
accomplish eradication of HGD and intramucosal
esophageal cancer with three to four applications of
CSATM therapy. Recent work presented at the 2010
OESO World Congress suggests an ability to accom-
plish this with less than three treatments, on average,
and this may reflect advantages gained by the shift
toward a dosimetry of 2 × 20 sec yielding a more ro-
bust treatment response than 4 × 10 sec sprays. Cer-
tainly, we await the full results from Ribiero et al.13
as they study more patients undergoing esophagec-
tomy in an effort to confirm whether 2 × 20 sec
dosimetry will continue to consistently demonstrate
full thickness mucosal necrosis. If proven in subse-
quent patients, this full thickness histology would
confirm that which we see endoscopically and so-
lidify our ability to embrace this as our standard
noncancer dosimetry. And with regard to acid con-
trol, we should aim to control acid exposure in
all patients undergoing any ablation procedure—
whether radiofrequency, resectional procedures, or
cryotherapy—to ensure the greatest opportunity for
healing with a neosquamous epithelium.
5. Endoscopic spray cryotherapy for
esophageal cancer: cure or palliation?
Bruce D. Greenwald
bgreenwa@medicine.umaryland.edu
This review discusses the use of low-pressure en-
doscopic spray cryotherapy with liquid nitrogen
(CryoSpray Ablation System) for the treatment of
esophageal cancer. With this technique, esophageal
tissue is frozen with liquid nitrogen delivered in a
noncontact method via a catheter passed through
the working channel of a standard upper endoscope.
In cancer, tissue is typically frozen for 20 sec, al-
lowed to thaw completely (approximately one min)
then refrozen repeatedly, typically in at least three
freeze-thaw cycles. These cycles induce tissue necro-
sis by direct freezing (protein denaturation, extracel-
lular and intracellular ice formation, cell membrane
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disruption), tissue necrosis (vascular stasis, platelet
aggregation, and thrombosis), and cryotherapy-
induced apoptosis. The procedure is performed us-
ing standard endoscopic sedation and techniques in
the outpatient setting. To vent nitrogen gas formed
by evaporation during the procedure, a modified
orogastric tube (cryodecompression tube) is placed
prior to spraying and removed after treatment.
Endoscopic treatment sessions are repeated every
four to six weeks as needed.
The first case of endoscopic spray cryotherapy
in esophageal cancer was reported by Cash et al. in
2007.15 A 73-year-old man with previous T2N1 ton-
sillar cancer seven years prior and T4N0 esophageal
squamous cell carcinoma three years prior, both
treated with concurrent chemotherapy and exter-
nal beam radiotherapy, presented with a T2N0
esophageal squamous cell carcinoma outside the
field of the previous esophageal cancer. He was
treated with two sessions of cryotherapy and re-
mained disease free for over two years. He developed
an esophageal stricture from treatment that required
dilation and placement of a temporary esophageal
stent.
The largest reported study on the use of en-
doscopic spray cryotherapy in esophageal cancer
was published earlier this year.8 In this retrospec-
tive study, 79 patients from 10 sites around the
U.S. were treated. These patients failed, refused, or
were not candidates for standard therapy, includ-
ing chemotherapy, radiation therapy, or esophagec-
tomy. In this cohort, 74 (94%) had adenocarcinoma,
5 (6%) had squamous cell cancer, and 64 (81%) were
male. Median age was 76 (range 51–93) years, and
tumor stage at enrollment was T1: 60 (T1a: 33, T1b:
23, not specified: 4; T2: 16, T3/4: 3. Many partici-
pants were treated with previous therapy including
endoscopic mucosal resection: 27 (42%), concur-
rent chemotherapy/external beam radiotherapy: 12
(19%), photodynamic therapy (PDT): 11 (17%), ex-
ternal beam radiotherapy alone: 7 (11%), concur-
rent chemotherapy and external beam radiotherapy
then esophagectomy: 2 (3%), argon plasma coagula-
tion (APC): 2 (3%), and one each for chemotherapy
alone, esophageal stent, and RFA.
An efficacy cohort of 49 participants completed
treatment, either through endoscopic and biopsy-
confirmed tumor eradication (CR) or because of tu-
mor progression, patient preference to stop therapy,
or comorbid condition precluding further therapy
(treatment failure). In this group, tumor stage was
T1: 36 (T1a: 24, T1b: 10, not specified: 2); T2: 10,
T3/4: 3. Overall CR was 61.2%, including 72.2% for
T1 tumors (T1a: 75%, T1b: 60%). Mean follow-up
was 10.6 months for all and 11.5 months in the T1a
group. The median number of cryotherapy sessions
needed to produce a CR was three. Concurrent treat-
ments at the time of cryotherapy included endo-
scopic resection: 9, external beam radiotherapy: 2,
argon plasma coagulation: 3, RFA: 2, and esophagec-
tomy: 4. In a number of patients, cryotherapy was
not able to eradicate the tumor but was able to slow
or halt tumor progression for extended periods of
time, over one year in some cases. In a safety analy-
sis including 332 treatments for the 79 participants,
no serious adverse events were reported. Esophageal
stricture developed in 10 (13%), with 9/10 noted to
have esophageal narrowing due to previous treat-
ment prior to initiation of cryotherapy.
An earlier study of spray cryotherapy included
five patients with intramucosal carcinoma.16 Three
of five responded to the treatment, downgrad-
ing histology to IM without HGD or carcinoma.
Another study, primarily assessing safety and toler-
ability of spray cryotherapy in 77 patients, included
treatment data on seven patients with intramucosal
or mucosal carcinoma.5 Cancer was eliminated in
all patients and IM was eliminated in 5/7 (although
follow-up was limited).
Limited data are available on the use of spray
cryotherapy for debulking of advanced esophageal
neoplasms. Treatment in this setting is technically
challenging due to luminal stenosis and the presence
of the cryodecompression tube, which may make
scope manipulation difficult.
In summary, liquid nitrogen spray cryotherapy:
• eradicates T1a (mucosal) esophageal adenocar-
cinoma in 75% of cases;
• can be used in T1b (submucosal) disease, but
risk of lymph node metastasis must be consid-
ered;
• is probably no better than other ablation modal-
ities for palliation of bulky esophageal cancers,
but experience is limited; and
• appears to cause tumor regression for extended
periods even if eradication is not possible.
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Table 2. In multiple studies, RFA has resulted in no subsquamous glandular mucosa
Buried Stricture
N FU CR-IM CR-D CR-HGD glands rate
AIM-II trial25 61 30 months 98.4% None 0%
50 60 months 92% None 0%
AIM-LGD96 10 24 months 90% 100% None 0%
HGD Registry 92 12 months 54% 80% 90% None 0.4%
AMC-I30 11 14 months 100% 100% None 0%
AMC-II31 12 14 months 100% 100% None 0%
Comm Registry68 429 20 months 77% 100% None 1.1%
EURO-I69 24 15 months 90% 100% None 4.0%
EURO-II32 118 12+ months 96% 100%
Emory70 27 <12 months 100% 100% None 0%
Dartmouth71 25 20 months 78
Henry Ford33 66 Varied 93% None 6.0%
Mayo34 63 24 months 79% 89% None 0%
LGD72 39 24 months 87% 95% None 0%
HGD36 24 23 months 67% 79% None 0%
AIM RCT (primary)27 127 (RFA84) 12 months 77% (83%) 86% (92%) 5.1% 6.0%
Long-term FU73 106 24 months 93% 95% 3.8% 7.6%
EMR vs. RFARCT38 22 24 months 96% 96% None 14%
member for CSA Medical, Inc., the manufacturer of
the CryoSpray Ablation system.
6. Compared to other thermal ablation
modalities, what is the rate of development





• Incomplete ablation by any method may result
in the glandular mucosa getting “buried” under
regenerating neosquamous epithelium.
• This subsquamous glandular mucosa may not
be visible endoscopically.
• Inadequate endoscopic surveillance may lead to
development of undetected malignancy.
Argon plasma coagulation
In several series, incidence of subsquamous glan-
dular mucosa after APC ablation varies between
4–44%.17–21 The key factors predicting lower in-
cidence with APC are higher power settings, higher
PPI dose, and shorter Barrett’s segment.
Photo dynamic therapy ablation and
multipolar electro coagulation
Three series compared APC versus PDT; PDT had
between 4% and 24% incidence of subsquamous
glandular mucosa.18–20 In addition, the PHOBAR
Trial compared PDT with porfimer sodium com-
bined with acid suppression (PHOPDT) to acid
suppression alone (OM) in patients with HGD.
At baseline, 5.8% of patients in the PHOPDT
group, and 2.9% of patients in the OM group
had SSIM. After treatment, the percentage of pa-
tients with squamous overgrowth increased, but
there was no significant difference between the two
groups: PHOPDT (30%) and OM (33%) groups
(P = 0.63).21
The data on the incidence of subsquamous glan-
dular mucosa after MPEC therapy are limited.
Sharma et al. reported SSIM in 27% of NDBE/LGD
patients (3/11) who had undergone MPEC and
achieved endoscopic and histologic cure (mean
follow-up of 24 months after endoscopic reversal
of Barrett’s).22
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Other key factors
• Adequate biopsy specimen must be obtained—
large capacity forceps are essential to sample
lamina propria.
• All of these thermal methods have an unaccept-
ably high incidence of subsquamous “buried”
glandular mucosa.
• There are reports of undetected subsquamous
adenocarcinoma developing after APC and
PDT.19,23,24
Radiofrequency ablation
In multiple studies, RFA has resulted in no sub-
squamous glandular mucosa (Table 2). AIM Trial at
2.5 years showed no subsquamous glandular epithe-
lium in nearly 4,000 total biopsy specimens.25 AIM-
II 5-year durability trial had 1,473 biopsy specimens
with no buried glands. A total of 85% of the spec-
imens included lamina propria or deeper tissue.26
The highest published post-RFA subsquamous glan-
dular mucosa rate to date is 5% of patients in the
AIM Dysplasia Trial, a randomized control trial that
evaluated RFA versus control (biopsy surveillance
and high-dose PPI acid suppression) in LGD and
HGD patients. At baseline, 25% of patients had
subsquamous glandular mucosa. At the 12-month
primary endpoint, this decreased to 5% in the
RFA arm and increased to 40% in the control
arm.34 Overall, in the published RFA literature,
which includes over 900 patients, there have been
six patients with post-RFA biopsy proven sub-
squamous glandular mucosa (one subsquamous
glandular mucosa containing fragment per pa-
tient).27–29 This translates to less than 0.7% of
patients having subsquamous glandular mucosa
post-RFA.28–39
7. What is expected from future technical
developments of the RFA technology




Current sizing balloon and procedure
In choosing the Halo360 ablation catheter for cir-
cumferential RFA, a sizing balloon is used to select
the appropriate catheter, which is made in five in-
ner diameter (ID) sizes: 18 mm, 22 mm, 25 mm,
28 mm, and 31 mm.40 Sizing is performed at 1 cm
intervals beginning at 12 cm above the esophago-
gastric junction measured as the top of the gastric
folds. At every sizing location, the Halo genera-
tor provides a measure of the esophageal ID and
recommends the ablation catheter size. Data are
recorded on a sizing worksheet, and the smallest rec-
ommended ablation catheter is selected. Generally
5–7 sizing steps are required, which adds 5–10 min
to the procedure.41 The sizing procedure is generally
safe, although it can cause some intraprocedural dis-
comfort and small amounts of bleeding associated
with breaks in the mucosa.26,42,43 When sizing and
ablation catheter selection are performed according
to instructions, circumferential ablation is a safe, ef-
fective procedure with a < 0.02% perforation rate
and no patient deaths.
Recent sizing balloon modification
A recent improvement in the sizing balloon involves
a change in the balloon material from polyethylene
terephthalate (PET) to the softer polyurethane (PU).
The earlier PET balloon could measure esophageal
ID to ≤ 33.7 mm, while the new PU sizing balloons
can measure esophageal ID to≤45 mm. This allows
better differentiation between the esophagus and
cardia.
Sizing balloon modifications under review
The current inflation pressure of the sizing bal-
loon is 4 pounds/square inch (PSI). A new mod-
ification is being considered that will decrease the
sizing balloon pressure to 3 PSI. The advantage of a
lower-pressure sizing balloon (25% less force ap-
plied to esophageal wall) would be to make it less
prone to migration within the esophagus and also
to further decrease the risk of mucosal tears and
bleeding. Using this method, the smallest size ab-
lation catheter should theoretically be used with
less stricture formation, although this risk is al-
ready low (0–6%). If this modification results in
more residual islands of Barrett’s mucosa, these
are still easily treated using the Halo90 focal RFA
device.
Circumferential use of larger focal ablation
device
Another way to improve the sizing balloon step
would be to avoid it altogether by using the Halo90
focal RFA device in a circumferential manner. The
Halo90 has a 13 mm × 20 mm footprint compared
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to the new Halo Ultra90 that has a 13 mm × 40 mm
footprint, allowing faster ablation of larger Barrett’s
areas.
Future concepts
The possibility of even larger Halo180 devices and
“one size fits all” balloon devices that unfurl or un-
roll to accommodate individual esophageal sizes and
shapes are also in the development pipeline, and
these would obviate the need for balloon staging.
8. What are the comparative adverse
effects of the diverse ablation procedures?
Srinadh Komanduri
koman1973@gmail.com
There has been an evolution in strategies for en-
doscopic ablation of dysplastic Barrett’s epithelium
and early intramucosal adenocarcinoma. The ad-
vances in endoscopic mucosal resection have lim-
ited ablative strategies to flat dysplastic disease. Prior
ablative strategies including multipolar electrocoag-
ulation (MPEC) and APC have fallen out of favor
due to lack of predictability as to depth of abla-
tion. PDT was the mainstay of ablative strategies for
many years. PDT has been very effective for treat-
ment of HGD, but it has carried a stricture rate up
to 30%, side effects of photosensitivity, nausea, and
dehydration.44 Furthermore, the risk of buried glan-
dular disease, which was reported frequently with
PDT, appears too extremely rare with newer tech-
nology such as RFA. RFA has the most thoroughly
investigated safety profile and safety reporting via
the ongoing registry.
Current overall complication rates are <0.25%
with stricture rate <1%, nearly nonexistent buried
glandular disease despite specifically sampling for
this, and minimal bleeding or perforation risk
(0.02%).26 Perforation really has not been a signif-
icant issue with any of the therapies but can occur
and generally is operator and technique dependent.
Finally, the newest therapy for ablation has been
cryotherapy. While data have been limited, a re-
cently published study evaluating safety and efficacy
of cryotherapy7 in HGD demonstrated strictures in
3% of patients, buried glands in 3% and one minor
case of bleeding. With both RFA and cryotherapy,
the strictures that have been reported have for the
most part been responsive to single balloon dilation.
Overall, the safety profile with RFA and cryotherapy
is significantly improved over PDT with RFA; cur-
rently with the most data in support of its safety
profile with RFA, cryotherapy is significantly im-
proved over PDT, and RFA currently with the most
data in support of its safety profile.
9. Is the potential rate of recurrence of
Barrett’s epithelium following ablation
currently known? What are the reasons for




Some papers use the term “recurrence,” but there is
currently no data to show if Barrett’s mucosa or
Barrett’s-associated neoplasia detected after abla-
tion represents recurrence or persistence. The more
precise term, incomplete response (IR), is recom-
mended, when findings such as Barrett’s epithelium
or neoplastic alterations are seen within a defined
interval after ablation.
Table 3. The results of radiofrequency ablation are
promising, but long-term follow-up is not yet available
Results of radiofrequency ablation (RFA)
Follow-up duration
Trial 1 year 2.5 years 5 years
AIM trial RFA27 CR-IM 70% CR IM CR-IM 92%
N = 60 98% N = 50
US Multicenter CR-LGD 90.5%
RFA CR-HGD 81%
CR-IM 77.4%
Velanovitch et al. CR-IM 93%
N = 60
US Multicenter CR-HGD 90.2%
for HGD CR-D 80.4%
CR-IM 54.3%
Sharma et al.22 CR-IM 70%
(eight centers)
N = 70
Roorda et al.14 CR-IM 46%
CR-D 71%
(CR, complete response; IM, intestinal metaplasia; LDG,
low-grade dysplasia; HGD, high-grade dysplasia; D, cys-
plasia).
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The results of radiofrequency ablation are
promising, but long-term follow-up is not yet avail-
able. Table 3 summarizes some of the recent papers
in this area.
A recent Cochrane review of a number of ablative
techniques summarized the results of 16 studies,
including 1,074 patients, with a mean number of
49 patients per study (range 8–108).45 Studies using
PDT had a mean eradication rate of 52% for BE
and eradication rates of dysplasia ranging between
56% and 100%. Factors that affected PDT efficacy
included variations in drug, light source, and dose
of light. Results reported for RFA included a mean
82% eradication rate of BE and a 94% eradication
rate of dysplasia.45
Factors that may affect detection of Barrett’s mu-
cosa following ablation include limitations of en-
doscopic identification, variations in biopsy strat-
egy and sampling, extent of ablation or incomplete
ablation, and buried Barrett’s glands that may re-
main below squamous re-epithelialization. There
are limits to standard white light endoscopy, which
can only identify luminal contour and luminal lin-
ing, visualizing columnar tongues, but lack the
resolution to differentiate subtypes of columnar
epithelium.
After squamous re-epithelialization, buried
glands cannot be seen without specialized en-
doscopic techniques, such as optical coherence
tomography (OCT). Follow-up biopsy strategy
must employ careful surveillance such as the Seattle
protocol, which includes four-quadrant large-jaw
biopsies at each 2 cm of esophagus previously
documented to have columnar metaplasia and at
each 1 cm of esophagus in patients with history of
neoplastic changes. Biopsies must be deep enough
to sample subsquamous lamina propria to rule
out buried Barrett’s glands or neoplasia, and it
appears that the rate of buried glands is similar
comparing postablation biopsies with sham/PPI
biopsies.46
Investigators in the AIM Dysplasia Trial reported
that 80% of biopsies post-RFA were deep enough
to evaluate for subsquamous glands; however, they
considered biopsies adequate if they included lam-
ina propria, muscularis mucosae, or submucosa.
Squamous mucosa was most apt to provide limited
or superficial biopsies. Subepithelial sampling was
present in only 78.5% of squamous-only samples,
compared to 98.8% of columnar mucosa samples
(P < 0.001). The investigators stated that “a biopsy
that included LP papillae was categorized as LP.”
Their figure 1F shows a tangentially oriented biopsy
of squamous mucosa that does not include subsqua-
mous tissue.46 If this figure is representative of a
portion of the samples that were deemed adequate,
more studies and longer follow-up are needed to
determine the rate and biologic potential of buried
glands post-RFA. It is also worth emphasizing that
these results are from experienced investigators us-
ing standardized procedures. We do not yet know
whether the excellent ablation results reported so
far can be achieved in other sites of practice and
whether they will be lasting results.
What factors have been associated with
“recurrence” (persistence)?
A total of 75% of “recurrences” after cryotherapy
or RFA were in cardia.47 This raises the question of
whether the GEJ may be harder to treat, or more dif-
ficult to biopsy and screen, than tubular esophagus.
Molecular signature may also be associated with dif-
ficulty in eradicating disease with RFA. Investigators
performed microdissection of mucosal biopsies and
studied a panel of 16 allelic imbalances in 21 pa-
tients with LGD and BE. If more than 75% of cells
carried mutations, the patients were more resistant
to RFA treatment, and additional treatment sessions
were needed to eradicate mucosa with mutations.48
Other reported associations with IR include longer
lengths of the Barrett’s segments, older age of the
patients, multifocality of dysplasia, obesity, location
of IM at the top of the gastric folds, and longer du-
ration of dysplasia prior to treatment. In one study
including pH control, adequate pH was achieved in
fewer than 50% of patients undergoing RFA, and ab-
lation efficacy was lower in patients with inadequate
pH control.14
In conclusion, endoscopic ablation appears to
achieve excellent rates of ablation of Barrett’s epithe-
lium and Barrett’s-associated neoplasia, however,
longer follow-up is needed to identify risk factors for
persistence and recurrence, using regular and care-
ful biopsy surveillance strategies. Additional inves-
tigation and clinical research is needed to optimize
control of esophageal pH, and to identify patients
at risk for IR or “recurrence,” including those with
longer segments and increased mutation rates. Bet-
ter strategies are also needed for surveillance of GEJ
and cardia.
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Figure 1. The low-grade dysplasia spectrum: not all things given the diagnosis of low-grade dysplasia are the same.
10. Given the low risk for cancer
development, should LGD be treated?
Henry D. Appelman
appelman@umich.edu
Actually, a more appropriate question is, “given the
low risk of cancer development, should LGD even
require more stringent surveillance?” In order to
answer this question, we need a clear definition
of LGD. The textbooks offer various definitions
that are filled with words like “slightly,” “reduced,”
“larger,” “minimal,” “more atypical,” “mild,” “ir-
regular,” and “inconspicuous” that are used to de-
fine LGD, yet these words have no clear meanings.
Therefore, definitions of LGD currently in print are
only marginally useful at best.
Regardless of these definitional problems, is it still
possible that, in practice, the diagnosis of LGD by
different pathologists is good enough for clinicians
to use in determining patient management? To begin
with, clinicians and pathologists have to recognize
that LGD is not a single entity but a group of epithe-
lial changes that look worse than normal, but they do
not look as bad as HGD. We know that the histologic
diagnosis of LGD has poor agreement even among
experienced pathologists.49 Presumably, LGD has a
lowest end and a highest end, and the highest end is
next to the lowest end of HGD. (Fig. 1)
This leads to other questions. Is the cancer risk
the same at both ends of the low-grade dysplastic
spectrum? Is the cancer risk for highest LGD like that
for the lowest HGD or is it more like the lowest LGD?
Clearly we don’t have answers to these questions,
because no study has separated LGD into the two
groups of highest and lowest ends and evaluated
cancer risk for each groups separately. The reason
why this has not been done is that no pathologist or
groups of pathologists know the criteria for epithelia
at both ends of the LGD spectrum. What is obvious
is that the diagnosis of LGD is not very dependable,
and so clinicians have to decide if they really want
to make patient care decisions based upon such an
undependable diagnosis.
Presumably, this has lead to the variability in rec-
ommendations for dealing with LGD. These rec-
ommendations vary from continuing endoscopic
biopsy surveillance every six months for LGD for
an indefinite period of time to antireflux therapy
followed by endoscopic surveillance every one to
three years. The Practice Parameters Committee of
the American College of Gastroenterology suggests
that LGD requires expert pathologist confirmation
with follow-up endoscopy at six months and yearly
endoscopy until there is no dysplasia on two consec-
utive yearly endoscopies.50. To emphasize the prob-
lems in histologic diagnosis of LGD, there is a recent
study from the Netherlands of 147 patients who had
a diagnosis of LGD from six community hospitals.
The biopsies were reviewed by two “expert” pathol-
ogists, who downgraded the diagnosis to negative or
indefinite for dysplasia in 85% of the cases.51 They
only agreed with the diagnosis of LGD in 15% of
these patients. In these 15%, there was an 85% cu-
mulative risk of progression to HGD or carcinoma
in 109 months compared to only a 5% risk at 107
months for those cases that were downgraded to
negative or indefinite. In another study from four
U.S. centers of 618 patients, 147 cases were diag-
nosed as LGD, but there was no central pathologist
review.52 In this study, it was concluded that the
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progression to carcinoma from LGD is not signifi-
cantly different from that of the entire group, most
of whom did not have dysplasia. This suggested that
LGD patients might have been managed similarly to
nondysplastic Barrett’s patients in terms of surveil-
lance.
To conclude, based upon this information, more
frequent follow-up is clearly indicated for cases of
LGD that have been verified by the two expert Dutch
pathologists, because there is a high risk of pro-
gression to HGD and carcinoma. However, regular
follow-up might be recommended for cases of LGD
from the four U.S. centers as long as they were not
reviewed by the Dutch pathologists, because of their
low-risk of progression.
11. What is the effect of continuous
therapy with PPIs compared to intermittent
prescription on the rate of progression of
BE to HGD and adenocarcinoma?
Helen M. Shields
hshields@caregroup.harvard.edu
The data supporting a chemopreventative effect of
acid suppression in BE leading to a reduction of the
risk of HGD and esophageal cancer are conflicting.
In 1996, using organ culture of endoscopic biopsies
of BE, Fitzgerald et al. showed that continuous acid
exposure resulted in increased villin expression, in-
dicating differentiation because villin is one of the
first cytoskeletal proteins to be localized to the api-
cal membrane in development and is widely used as
a marker of cell differentiation.53 They also showed
reduced cell proliferation as indicated by prolifer-
ating cell nuclear antigen expression (PCNA), sug-
gesting a differentiated phenotype.53
In contrast, short acid-pulses dramatically in-
creased cell PCNA expression and proliferation.
These authors concluded that variations in acid ex-
posure may contribute to the heterogeneity seen
both molecularly and structurally in Barrett’s pa-
tients. They postulated that acid suppression would
need to be effective enough to inhibit acid pulses
and cell proliferation. However, Lao-Sirieix et al.
found that long-term acid suppression reduces pro-
liferation in BE biopsy samples, but it had no ad-
vantageous effect on c-myc, apoptosis, or COX-2.54
Lao-Sirieix noted that the AspECT trial is impor-
tant because it will evaluate aspirin and esomepra-
zole for their effect on the risk of HGD and/or
esophageal cancer in a prospective, randomized
manner.54
Additional controversial results of the effect of
acid on proliferation were published in 2007 by
Feagins et al., who treated Barrett’s cells with short
exposures to acid.55 Acid exposure significantly de-
creased total cell numbers and resulted in cell cycle
prolongation that was associated with greater ex-
pression of p53.55 The authors concluded that acid
has p53-mediated, antiproliferative effects in non-
neoplastic Barrett’s epithelial cells.55 They spec-
ulated that antisecretory medication in dosages
beyond that necessary to heal esophagitis may be
detrimental rather than helpful. They called for
prospective clinical trials to determine the optimal
level of acid suppression in BE.55
In 2006, Cooper et al. reported that BE patients
who were continuously treated with PPIs had a low
incidence of adenocarcinoma (0.31%) compared to
previously published reports.56 However, de Jonge
recently published the largest reported nationwide
cohort of unselected patients from the Netherlands
with BE and found a 0.4% annual risk of cancer
in histologically proven BE patients, which is lower
than the frequently quoted 0.5% annual incidence
of cancer in Barrett’s patients.57 Male gender, older
age (greater than 75 years), and the diagnosis of
low-grade dysplasia are independent predictors of
malignant progression.57
In summary, the role of acid in increasing or de-
creasing proliferation is still controversial and un-
certain. Physicians must balance the safety of the
long-term use of PPIs in patients with BE and their
possible, but not proven, potential for decreasing
the risk of neoplasia over the long term. The an-
nual incidence of esophageal cancer in patients with
BE is lower than previously thought making com-
parisons to older and higher estimates of the risk
not useful for decision making. The results of the
10-year 2,513 patient prospective controlled trial
AspECT to be reported in 2014 will be of great im-
portance to making decisions concerning the use of
PPIs on a continuous basis to specifically decrease
the risk of HGD and adenocarcinoma in Barrett’s
patients.
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12. Can the role of RFA in ablating




Endoscopic ablative therapy for BE is a rapidly
evolving field featuring potentially landscape-
shifting technology for the care of these patients.
The prospect of improving care in BE is especially
enticing given that our practices have been largely
unchanged over the last 20 years, during which time
the incidence of esophageal adenocarcinoma, the
disease to which BE predisposes, has risen dramat-
ically.59 Because the technology to perform abla-
tion has evolved and become more accessible, and
because the morbidity associated with these proce-
dures is generally low, these therapies have gained in
popularity. However, considerable questions persist
about when in the course of BE these techniques
should be used, and which of the several available
techniques should be preferred.
It appears that ablation can change the natural
history of BE, at least in the short and midterm.
Multiple modalities have been demonstrated to ef-
fectively cause reversion of IM to neosquamous ep-
ithelium.59–62 Importantly, high-dose acid suppres-
sion with PPIs must be given in conjunction with
the treatments to induce this change.
Two modalities have been subjected to com-
parison with intensive endoscopic surveillance in
randomized controlled trials, PDT and RFA. Over-
holt et al.63 randomized 208 subjects with BE and
HGD in a 2:1 ratio to either treatment with a PPI, or
treatment with PDT plus PPI therapy. The primary
outcome was eradication of all HGD at any time
during follow-up. Secondary outcomes included
complete eradication of IM, cancer incidence, and
safety profile. Subjects were assessed with upper
endoscopy with biopsies every six months. The
mean follow-up in the PDT group was 24 months,
and in the PPI group, 19 months. Seventy-seven
percent of subjects in the PDT + PPI arm achieved
the primary outcome, compared to 39% in the
PPI group. Of treated subjects, 52% had complete
eradication of IM at some time during follow-up.
Cancer incidence was 13% in the PDT + PPI
group, compared to 28% in the PPI group, with all
differences between groups statistically significant.
Esophageal strictures occurred in 12% of subjects
undergoing one PDT treatment, and 38% after two
treatments. The authors concluded that PDT was ef-
fective in eradication of HGD, and decreased cancer
incidence.
A second study compared RFA to intensive en-
doscopic surveillance.42 One hundred and twenty-
seven subjects with either low-grade (n = 64) or
high-grade (n = 63) dysplasia were randomized in a
2:1 ratio to either RFA + PPI or PPI alone. The pri-
mary outcomes were complete eradication of dys-
plasia and IM at 12 months. Secondary outcomes
included cancer incidence and safety profile. Sub-
jects were assessed by upper endoscopy with biop-
sies every three months (HGD) or every six months
(low-grade dysplasia). In the treatment groups, 81%
(HGD) and 91% (LGD) achieved eradication of
dysplasia, and 77% achieved eradication of IM. In
contrast, 21% of controls achieved eradication of
dysplasia, and 2% achieved eradication of IM. The
cancer risk at one year was 9.3% in controls and
1.2% in treated patients (P < 0.05 for all).
A recent study assessing the ability of cryother-
apy with liquid nitrogen also presented promising
results. Of 98 patients with BE and HGD treated
at 10 U.S. sites, 97% were able to be made free of
HGD, 86% were free of all dysplasia, and 57% were
free of all IM. The side effect profile of the treatment
was favorable, with no perforations, three strictures,
and two subjects with chest pain managed with nar-
cotics. For ease of use, efficacy, and cost, current
data suggest that RFA is a logical choice for abla-
tive therapy in BE. It has a side effect profile supe-
rior to that of PDT, with fewer strictures. Efficacy
data from rigorous studies demonstrate efficacy as
good, or better, than other forms of ablation, and
the balloon-based device allows treatment of even
long segments of disease in a time-effective manner
compared to other devices.
But which patients deserve consideration as can-
didates for ablation? Is the only good BE burned
BE, even if it was nondysplastic before combusted?
Both cost-effectiveness analysis data,64 as well as the
data from trials reviewed above, suggest that sub-
jects with HGD are reasonable candidates. While
cancer risk is substantially lower in subjects with
low-grade dysplasia, certain subgroups of LGD sub-
jects may also deserve consideration. Multifocal dis-
ease, dysplasia confirmed by multiple pathologists,
and longer segment disease have all been suggested
as potential risk factors for progression in LGD.
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Interestingly, even among subjects with nondys-
plastic disease, cost-effectiveness data suggest that
ablative therapy may confer a survival advantage
at a reasonable cost.64 The treatment of nondys-
plastic patients faces an especially high bar, because
the vast majority of these subjects will never de-
velop cancer.65 Therefore, any treatment directed
at this subgroup needs to be safe, reasonably
priced, and effective. Although this appears to be
a formidable task, ablation may in fact turn out
to be preferable to our current strategy of endo-
scopic surveillance,66 because of the high costs as-
sociated with endoscopic surveillance, as well as
the extremely high costs and mortality associated
with the development of esophageal adenocarci-
noma. This is especially true if endoscopic surveil-
lance intervals can be altered after successful ab-
lation. However, to date, vitally needed outcomes
data regarding the efficacy of ablation in less se-
vere forms of Barrett’s make it impossible to draw
firm conclusions about the role of these therapies
in subjects with nondysplastic Barrett’s and those
with LGD.
Much remains unknown regarding the utility of
ablative therapy in Barrett’s. Although preliminary
data suggest that in both dysplastic and nondysplas-
tic Barrett’s, the neosquamous epithelium is durable
in mid-term results,26,67 further work will define
the long-term durability of the neosquamous rever-
sion. The cancer risk in treated subjects requires
further definition. As noted above, further work
will be necessary to optimize candidate selection.
Until these issues are settled, the use of ablative
technologies in BE will continue to be an evolving
picture.
13. What are the current indications for




In the past five years a number of institutions have
utilized cryo-ablative therapies to destroy unwanted
malignant tissues. In general, there are five reports
that contain the bulk of the information that is so
often referred to when discussing the use of cryo-
ablation. These reports are as follows:
• Greenwald et al.8 (10 centers, 79 pts with
LGD, HGD, adenocarcinoma—curable but
inoperable)
◦ Endoscopic spray cryo-therapy for esopha-
geal cancer – safety and efficacy. GIE 2010
• Greenwald et al.5 (4 centers, 77 patients with
adenocarcinoma/SCC T1, T2, T3—inoperable)
◦ Safety, tolerability and efficacy of endoscopic
low-pressure liquid nitrogen spray cryother-
apy in the esophagus. Diseases of the Esoph-
agus 2010
• Shaheen et al.7 (9 centers, 98 pts with HGD—
curable)
◦ Safety & efficacy of endoscopic spray
Cryotherapy for BE with HGD. GIE 2010
• Dumot et al.16 (1 center, 30 pts with HGD,
Adenocarcinoma—curable but inoperable)
◦ CSA for Barrett’s esophagus with HGD and
early esophageal carcinoma in high risk pa-
tients. GIE 2009
• Johnston et al.12 (1 center, 11 pts with BE with
or without dysplasia—eradicatable)
◦ Cryo-ablation of Barrett’s esophagus: a pilot
study. GIE 2005
All together, these five reports provide 230 patients
with some type of “bad” esophageal disease. The
company itself, C.S.A. Medical of Baltimore Mary-
land provides a “cryo-therapy ablation kit” pam-
phlet that contains the indications, contraindica-
tions and warnings as well as instructions on the use
of cryo-therapy. The stated indications for use are
contained in a simple generalizable sentence: “The
CSA System is intended to be used as a cryosurgi-
cal tool for the destruction of unwanted tissue in
the field of general surgery, specifically endoscopic
applications.”
The stated contraindications are somewhat
lengthier (Table 4). Of interest is the way a large
insurance company looks at use of newer therapies
such as cryo-ablation. Aetna Insurance Company in
their Clinical Policy Bulletin for Barrett’s esophagus
surgery states the following:
1. Aetna considers any of the following interven-
tions medically necessary for the treatment of
members with Barrett’s esophagus who have
HGD when medical therapy (e.g., PPI’s, H-2
RA’s, or prokinetic agents) has failed:
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d. endoscopic mucosal resection
e. radiofrequency ablation
2. Aetna considers any of the following ablative in-
terventions experimental and investigational for
the treatment of members with Barrett’s esoph-
agus because their effectiveness for this indica-
tion has not been established:





The wisdom and basis of these decisions is beyond
the scope of this paper. Indeed, a conference of
endoscopic investigators charged with determining
Table 4.
Category Contraindication
General • During pregnancy
• Where food is identified in
the stomach or proximal
duodenum at the time of
the procedure and cannot
be removed.
• In any application in which
use of the active suction
module is inappropriate.
Compromised Tissue • Where significant
esophageal ulceration or




• Where any procedure or
anatomy has significantly
reduced or restricted the
volume of the stomach,
including, but not limited
to, gastric bypass, stomach
stapling and
gastrojejunostomy
• Where any disease state has
significantly reduced the
elasticity in the GI tract
(e.g. Marfan’s Syndrome).
which therapies should and should not be approved
would likely make for a very entertaining weekend.
Discussion
Large-scale studies on the benefits of cryo-ablation
therapy (or any ablative therapies) are unlikely to
be performed soon, and even more unlikely to be
funded. In all likelihood, the role of ablative ther-
apies, including cryo-ablation, will be defined by a
large number of individual experiences, most im-
portant of which would be the safety of the method.
Until that time, individual and group experience
will be the source upon which we depend. With the
knowledge that some therapies considered safe to-
day may have unrecognized long-term deleterious
effects, I offer some morsels of food for thought:
Our everyday beloved sun provides us with light
and warmth.
But, our treasured sun also provides a high
energy assault on our human tissues.
The modalities we use to destroy the evil
Barrett’s. . .
–MPEC, heat, APC, laser, PDT, radiofrequency,
freezing–
Also provide a high energy assault on our
human tissues.
And
Skin cancer is linked not so much to chronic
exposure,
But rather to a single severe sun burn from years
earlier. . .
perhaps to that one really bad burn—when you
were a teen.
Conclusion
Without evidence for or against the long-term ben-
efit of ablation of Barrett’s dysplasia, I offer the fol-
lowing, which is important to recognize is based
only on feelings and opinion. In cryo-ablation (or
any ablation) of Barrett’s Esophagus, the risks must
not outweigh the potential benefits:
1. For Barrett’s adenocarcinoma: each patient
must be considered individually; the decision
to use cryotherapy is a matter between patient
and physician.
2. For Barrett’s high-grade dysplasia: the lifetime
risk of developing AdCa is high; cryoablation
therapy is one of several modalities that may
prevent the development of cancer.
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3. For Barrett’s low-grade dysplasia or less: The
lifetime risk of developing adenocarcinoma is
low; aside from selected cases, routine cryo-
ablation therapy cannot be justified.
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